The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity.
about
Synthetic Strategies for 5- and 6-Membered Ring Azaheterocycles Facilitated by Iminyl RadicalsPhase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agentsDesign and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents.Metabolic pathways of the camptothecin analog AR-67The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.Anti-proliferative and apoptosis-inducing effects of camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester in human breast tumor MCF-7 cells.Camptothecins in clinical development.Camptothecin and its analogues: a review on their chemotherapeutic potential.Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.Cyclization-activated prodrugs.Factors affecting the stability of drugs and drug metabolites in biological matrices.Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.Progress in the medicinal chemistry of silicon: C/Si exchange and beyond.DNA topoisomerase-targeting chemotherapeutics: what's new?Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67.Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?Silicon-containing analogs of camptothecin as anticancer agents.Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.3D-QSAR study of 20 (S)-camptothecin analogs
P2860
Q26746980-0BD7A6C1-CB4D-49C9-8B31-EB2A88517143Q33380081-C0B01A5E-4000-48AF-8BD3-ABE0FC1B05B8Q33387815-9831B556-4859-4C62-8C30-A91918D1C3C5Q33841304-56E4673E-742D-48D0-A79F-0CA6EE70CC2EQ34036266-3D0C8DCD-2E3F-488A-BFF3-317E4C7A9250Q34715481-AF8AA149-7D06-4308-9EDA-C5B919FA52AEQ34928276-7B4AA372-2991-4372-8E58-3AE2ABBE2807Q35152747-B99919D7-410B-4457-8F19-E0BA7CBF64B7Q35688238-AA2FD2A0-0FC3-4830-8C51-60FB55D928C8Q36153120-4B783233-BE27-4562-99AC-8F513106FCFCQ36838603-1B55D4DF-9DA1-4625-A06C-BEBBE2299E88Q36935258-DF8D9C8B-B6E3-4E1B-817C-81B8B0FC4C76Q37027131-B5C50651-C87A-4A7A-95E6-B05D4E802B42Q37810212-BCCFFB81-C39D-4561-861A-1E56E2858A61Q38637981-EDB1D980-48B7-4F1E-ABAD-28090D824310Q38712547-DEBCA3B7-33D0-47EC-BB59-C07E0FEA7637Q38737295-D6B0C61B-EADF-4495-887F-DCBE825E2F66Q39320242-C8BE4864-FAA8-4BB6-912D-52A2CB3F7DAEQ39508657-0DE99E92-6CA8-4F4F-A944-3AB0A8C18BD7Q40562765-302E20CE-AAB3-4E02-B171-3232F6A989FEQ42103426-4AC21E5D-ACCD-4F9D-99C0-E77419CE483EQ44076450-7F407632-A443-4A33-96EB-1E0AD959F9E6Q45349901-A8E5E1E7-02DB-477F-8A11-9CC92EC10B69Q46780138-94CBF470-2012-44C7-9032-24FBA33BCECCQ47220295-DA80E105-1D69-483B-B01B-1F9643F4EA57Q48120322-2005483D-180D-4FB3-A7AF-64F8D3B8631DQ51730628-95B7C9FD-6AC6-491C-9D6F-66AD03B3EE9CQ54943623-68934869-3418-4ABD-BEA7-8D967674F914Q56864508-EE66E37D-DF25-471B-A5B0-B050BB03D6C4
P2860
The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@ast
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@en
type
label
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@ast
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@en
prefLabel
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@ast
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@en
P2093
P356
P1476
The novel silatecan 7-tert-but ...... nd potent anticancer activity.
@en
P2093
Bingcang AL
Kohlhagen G
Kruszewski S
P304
P356
10.1021/JM000144O
P407
P577
2000-10-01T00:00:00Z